Related Experiment Video
Updated: Mar 20, 2026
A Rat Carotid Artery Pressure-Controlled Segmental Balloon Injury with Periadventitial Therapeutic Application
Published on: July 9, 2020
Paclitaxel-Coated Balloons: Review of a Promising Interventional Approach to Preventing Restenosis in Femoropopliteal
Mohamed Teleb1, Miraie Wardi1, Sucheta Gosavi2
1Department of Internal Medicine, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center, El Paso, Texas.
Insights
Drug-eluting balloons (DEBs) show promise in preventing restenosis for peripheral arterial disease (PAD) patients undergoing femoropopliteal interventions. DEBs reduced restenosis and target lesion revascularization compared to uncoated balloons, offering a potential advancement in PAD treatment.
Area of Science:
- Vascular Medicine
- Interventional Cardiology
- Biomaterials Science
Background:
- Peripheral arterial disease (PAD) is a significant global health concern, causing morbidity and mortality, often linked to diabetes and hypertension.
- Current treatments for severe PAD include revascularization, but restenosis and complications like critical limb ischemia remain challenges.
- Drug-eluting balloons (DEBs) represent a novel interventional strategy aimed at mitigating post-procedure restenosis.
Purpose of the Study:
- To review clinical trials assessing the efficacy and safety of drug-eluting balloons (DEBs) for femoropopliteal arterial interventions.
- To compare restenosis rates, late lumen loss (LLL), and target lesion revascularization (TLR) between DEBs and conventional uncoated balloons.
- To evaluate the potential of DEBs as an interventional approach for managing peripheral arterial disease.
Main Methods:
- Systematic review and meta-analysis of clinical trials evaluating DEBs in femoropopliteal arteries.
- Focus on studies reporting restenosis rates, LLL, and TLR.
- Exclusion of below-the-knee (BTK) intervention studies.
Main Results:
- Pooled data indicate an average restenosis rate of 25% and 0.3 mm late lumen loss (LLL) with DEBs.
- Drug-eluting balloons demonstrated a 14% reduction in target lesion revascularization (TLR) compared to uncoated balloons.
- The review focused on femoropopliteal interventions, excluding BTK disease.
Conclusions:
- Interventional treatment of PAD using drug-eluting balloons appears promising for reducing restenosis.
- DEBs show a favorable safety and efficacy profile in femoropopliteal interventions.
- Further large-scale studies are necessary to confirm long-term outcomes and optimize the use of this technology.
Abstract:
Peripheral arterial disease (PAD), a major cause of morbidity and mortality worldwide, is characterized by intermittent claudication and is associated with chronic diseases such as diabetes and hypertension. The goal of treatment is to address the underlying cause and to modify risk factors. Although medical management is the first-line treatment of PAD, some individuals may have severe symptoms and require revascularization with percutaneous transluminal angioplasty with or without stent placement or surgery. Interventional approaches may, however, be associated with high prevalence of restenosis and subsequent complications such as critical limb ischemia and amputation. Drug-eluting balloons (DEBs) are a new interventional technology with the primary goal of preventing restenosis. We review the clinical trials and studies that assessed the efficacy and safety profile of DEB and will focus on the restenosis rate in femoropopliteal arteries including target lesion revascularization (TLR) and late lumen lesion (LLL) using different modalities of intervention such as stents and DEB. Average data collected from the trials reported included restenosis rate of 25%, 0.3 mm LLL, and 14% reduction in TLR with DEB versus uncoated balloons. Below the knee (BTK) only intervention studies were excluded from this review as endovascular approach is usually reserved for critical limb ischemia for BTK disease. Interventional approach to treat PAD with DEB appears to be a promising technology. Additional larger studies are needed to further define safety, efficacy, and longer term outcome with this novel technology.
More Related Videos
13:48Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound
Published on: April 21, 2023
04:30A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
Related Concept Videos
01:27Peripheral Artery Disease III: Interprofessional Care
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:23Peripheral Artery Disease V: Postoperative Nursing Management